Study of Recalled Essure Implant Continues to Lose Participants, But FDA Reports Measures to Fix Data are Working
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Interim Essure Study Shows More Than 1-in-5 Women Suffer Allergic or Hypersensitivity Reactions: FDA July 9, 2020 Irvin Jackson Add Your Comments An ongoing study involving problems with Essure birth control suggests that more than 20% of women implanted with the device may be suffering allergic or hypersensitivity reactions, facing an increased risk of chronic abdominal pain and abnormal bleeding and higher rates of gynecological surgical procedures, according to federal regulators. On July 8, the FDA issued a press release about the interim results of a mandated Essure postmarket surveillance study. While the data is still evolving, the preliminary results seem to confirm a number of serious problems with the Bayer birth control device, which is no longer available on the market. Learn More About Essure Implant Lawsuit Problems with Essure birth control implant may cause painful complications. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Essure Implant Lawsuit Problems with Essure birth control implant may cause painful complications. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Essure was previously sold by Bayer as a permanent form of birth control, involving flexible coils inserted into the Fallopian tubes. It was used during a procedure designed to cause scar tissue to develop, which blocks the tubes and prevents insemination. However, the device was removed from the market amid thousands of Essure lawsuits filed by women who experieced painful and debilitating complications, including migration injuries, perforations, severe reactions and other problems. Although Essure was recalled from the market in most countries in 2017, Bayer continued to sell the device in the United States until the end of 2018. In the face of mounting pressure and publicity about the injuries women were experiencing from Essure, the company announced in July 2018 that it was removing Essure from the US. market on December 31, 2018. Following the decision, the FDA confirmed Bayer would be required to extend a post-market surveillance study and take other measures to ensure long-term Essure oversight well after production and sales have ceased. Essure Study Results The open-label, non-randomized observational cohort study compares the use of the Essure implant with laparoscopic tubal sterilization (LTS). It involved women who were at least 21 years old and who had not been pregnant within the previous six weeks before participation in the study. Followup of the 1,128 subjects will be conducted over 60 months. Enrollment in the study ended December 31, 2019. The interim results indicate that 22.3% of women who received the Essure reported suffering allergic or hypersensitivity reactions, compared to only 12.5% in the LTS group. The results also revealed that 9.1% of the Essure subjects suffered chronic lower abdominal pain or pelvic pain, compared to 4.5% in the LTS group, and found that 16.3% of the Essure patients reported abnormal uterine bleeding, compared to 10.2% in the LTS group. “Early results show that Essure patients tend to have higher rates of chronic lower abdominal and/or pelvic pain and abnormal uterine bleeding compared to women who had laparoscopic tubal ligation as their permanent birth control,” Dr. Terri L. Cornelison, director of the FDA’s health of Women Program, said in the press release. “Also, patients with Essure had higher rates of gynecologic surgical procedures—including surgery to remove Essure—than patients who had tubal ligation.” The interim findings indicate about 14.3% of Essure recipients had the device removed within the first 21 months. However, only 1.9% suffered unintentional organ perforation, though that was nearly double the 1.1% rate in the LTS group. Both procedures appeared to be highly and virtually equally effective at preventing pregnancies. The subjects of the study will continue to follow up with researchers every year for the next five years. Bayer currently faces more than 18,000 product liability lawsuits filed by women nationwide, each involving similar allegations that the Essure birth control coils were unreasonably dangerous and defectively designed. With approximately 750,000 women worldwide implanted with the device, and about 70% of those procedures in the United States, the size and scope of the litigation may continue to increase as Essure causes problems for women with the device in their body. Tags: Bayer, Birth Control, Essure, Hypersensitivity, Pregnancy Image Credit: Image via <a href="http://www.shutterstock.com/gallery-3015638p1.html?cr=00&pl=edit-00">Lukassek</a> / <a href="http://www.shutterstock.com/editorial?cr=00&pl=edit-00">Shutterstock.com</a> More Essure Lawsuit Stories Study of Recalled Essure Implant Continues to Lose Participants, But FDA Reports Measures to Fix Data are Working November 1, 2023 Progress of Essure Birth Control Implant Post-Marketing Study “Inadequate,” FDA Warns Bayer October 11, 2022 85% of Bayer Essure Adverse Event Reports Submitted Last Year Linked to Device Removal: FDA March 16, 2022 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025) Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025) Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)
Study of Recalled Essure Implant Continues to Lose Participants, But FDA Reports Measures to Fix Data are Working November 1, 2023
Progress of Essure Birth Control Implant Post-Marketing Study “Inadequate,” FDA Warns Bayer October 11, 2022
85% of Bayer Essure Adverse Event Reports Submitted Last Year Linked to Device Removal: FDA March 16, 2022
Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)
Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)
Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)